.Pharmacolibrary.Drugs.ATC.J.J05AP52 .Pharmacolibrary.Drugs.ATC.J.J05AP52| name: | DasabuvirOmbitasvirParitaprevirAndRitonavir |
| ATC code: | J05AP52 | route: | oral |
| n-compartments | 2 |
Dasabuvir, ombitasvir, paritaprevir, and ritonavir is a fixed-dose combination regimen used as antiviral therapy for chronic hepatitis C virus (HCV) infection. Paritaprevir (an NS3/4A protease inhibitor) is boosted with ritonavir (a CYP3A inhibitor), ombitasvir is an NS5A inhibitor, and dasabuvir is a non-nucleoside NS5B polymerase inhibitor. This fixed combination (also marketed as Viekira Pak) is approved for the treatment of HCV genotype 1 and was widely used but has been largely superseded by newer regimens.
Pharmacokinetic parameters for healthy adult subjects after oral administration (fed state). Parameters are predominantly derived from population PK and single/multiple dose studies.
Mensing, S, et al., & Dutta, S (2016). Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies. The AAPS journal 18(1) 270–280. DOI:10.1208/s12248-015-9846-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26597291
Minaei, AA, & Kowdley, KV (2015). ABT-450/ ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus. Expert opinion on pharmacotherapy 16(6) 929–937. DOI:10.1517/14656566.2015.1024653 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25800085
Brayer, SW, & Reddy, KR (2015). Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy. Expert review of gastroenterology & hepatology 9(5) 547–558. DOI:10.1586/17474124.2015.1032938 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25846301